Amgen Inc (HKSE:04332)
HK$ 1761 0 (0%) Market Cap: 1.17 Til Enterprise Value: 1.57 Til PE Ratio: 35.86 PB Ratio: 20.00 GF Score: 92/100

Amgen Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 12, 2019 / 06:20PM GMT
Release Date Price: HK$1000
Terence C. Flynn
Goldman Sachs Group Inc., Research Division - MD

Okay. Great. I think we're going to get started, but thanks for joining us for our session with Amgen. I'm Terence Flynn, one of the biotech analysts here at Goldman, and we're very pleased to have Dave Reese, who's Executive Vice President of R&D for Amgen. And with that, I'm going to turn it over to Dave for some opening remarks, and then we'll dive into questions.

David M. Reese
Amgen Inc. - Executive VP of Research & Development

Well, thanks, Terence. It's a pleasure to be here today. Let me just make a few comments about our approach to R&D. I've been the head of R&D for just about a year now. And how do I conceptualize R&D in our industry as it exists now and projecting out 10 or 15 years? Well, to me, there are 2 core existential problems that we need to solve. One of them is how do we improve the success rates? Currently, they still run around 8% and it's been that way for some time. That varies by therapeutic areas, but we must do better. And then two, how do we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot